M2 Biologics

M2 Biologics is a biotechnology company specializing in the development of advanced regenerative medicine products for orthopedic and spinal surgery. The company's core technology centers on M2-10, a recombinant human bone morphogenetic protein (rhBMP-2/7) heterodimer. This specific protein configuration is designed to be more biologically active and potent than traditional homodimer BMP treatments, potentially allowing for lower dosages and improved safety profiles in bone repair. M2 Biologics focused on addressing clinical needs in spinal fusion and complex bone fractures. In May 2017, the company was acquired by Aziyo Biologics to integrate its protein engineering capabilities into Aziyo's regenerative medicine portfolio.